Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-10-26Clinical Trial Update: Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008 [Phase 2]
Phase 2 trial evaluating the combination of docetaxel and imatinib mesylate in metastatic castration-resistant prostate cancer that progress…
-
CLINICAL_TRIALS trial_result · 2012-10-12Clinical Trial Update: Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases [Phase 2]
This Phase 2 trial update evaluates docetaxel with or without imatinib mesylate in patients with androgen-independent (castration-resistant)…
-
FDA approval · 2012-10-04FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for JEVTANA (cabazitaxel) submitted by Sanofi-Aventis U.S. LLC, signaling a regulatory update to the…
-
CLINICAL_TRIALS trial_result · 2012-10-01Clinical Trial Update: Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer [Phase 2]
A Phase II clinical trial evaluating Abraxane (paclitaxel protein-bound particles) as front-line therapy for metastatic castration-resistant…
-
CLINICAL_TRIALS trial_result · 2012-09-28Clinical Trial Update: A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer [Phase 2]
Phase II trial update reporting results for sorafenib in metastatic, androgen-independent prostate cancer (CRPC).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-09-24Clinical Trial Update: Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases [Phase 3]
Phase 3 trial update comparing strontium-89 with external-beam radiation therapy in men with metastatic castration-resistant prostate cancer…
-
FDA approval · 2012-09-17FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for ZYTIGA (abiraterone acetate) to expand its indication for metastatic castration-resistant pr…
-
CLINICAL_TRIALS withdrawal · 2012-09-17Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
A Phase 2 trial evaluating enzalutamide in chemotherapy-naïve, symptomatic metastatic castration-resistant prostate cancer was withdrawn.
-
CLINICAL_TRIALS trial_result · 2012-08-29Clinical Trial Update: Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC [Phase 2]
Phase 2 trial evaluating OGX-011 in combination with second-line chemotherapy in hormone-refractory prostate cancer has completed and result…
-
CLINICAL_TRIALS trial_result · 2012-08-07Clinical Trial Update: Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen [Phase 3]
A Phase 3 trial evaluating satraplatin in hormone-refractory (castration-resistant) prostate cancer patients who had previously received one…
-
CLINICAL_TRIALS trial_result · 2012-07-18Clinical Trial Update: Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer [Phase 2]
This update reports the efficacy and safety results from a Phase 2 trial of Zactima (vandetanib) in patients with castration-refractory meta…
-
FDA label_change · 2012-07-03FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for ZYTIGA (abiraterone acetate) submitted by Janssen Biotech, Inc.
-
CLINICAL_TRIALS trial_result · 2012-05-31Clinical Trial Update: A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer [Phase 3]
Phase III trial evaluating Zibotentan (ZD4054) in combination with docetaxel for metastatic castration-resistant prostate cancer has complet…
-
CLINICAL_TRIALS trial_result · 2012-05-11Clinical Trial Update: PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC [Phase 2]
A Phase 2 trial of docetaxel with prednisone and sargramostim for hormone-refractory (castration-resistant) prostate cancer has been termina…
-
CLINICAL_TRIALS research · 2012-05-04Clinical Trial Update: Radiotherapy vs Observation for CRPC
This document provides an update on a trial comparing radiotherapy versus observation for castration-resistant prostate cancer. The current …
-
CLINICAL_TRIALS trial_result · 2012-04-27Clinical Trial Update: Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy [Phase 1]
Phase 1 safety study of a Cytotoxic Lymphocytes (CTL)–based therapy for castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS trial_result · 2012-03-30Clinical Trial Update: RNActive®-Derived Therapeutic Vaccine [Phase 1, Phase 2]
A phase 1/2 clinical trial of an RNActive-derived therapeutic vaccine for castration-resistant prostate cancer was terminated, with results …
-
CLINICAL_TRIALS trial_result · 2012-03-15Clinical Trial Update: Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate [Phase 2]
Phase 2 trial evaluating docetaxel, estramustine, and thalidomide in metastatic castration-resistant prostate cancer has completed enrollmen…
-
CLINICAL_TRIALS trial_result · 2012-03-12Clinical Trial Update: A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer [Phase 2]
A Phase 2 study evaluating the combination of Mycobacterium w and docetaxel in metastatic castration-resistant prostate cancer has been term…
-
CLINICAL_TRIALS trial_result · 2012-01-16Clinical Trial Update: Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer [Phase 1]
Phase 1 trial evaluating the combination of ipilimumab and GVAX in metastatic castration-resistant prostate cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2011-12-15Clinical Trial Update: Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer [Phase 2]
A Phase 2 study evaluating bafetinib (INNO-406) in patients with hormone-refractory prostate cancer has completed.
-
CLINICAL_TRIALS research · 2011-12-08Clinical Trial Update: The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer [Phase 2]
Phase 2 clinical trial update examining whether adding androgen deprivation therapy to docetaxel and prednisolone chemotherapy improves outc…
-
FDA approval · 2011-04-28FDA Approved: ZYTIGA — Original Application (Janssen Biotech, Inc.)
FDA approves ZYTIGA (abiraterone acetate) under NDA 202379, marking the original approval for metastatic castration-resistant prostate cance…
-
FDA approval · 2011-04-26FDA Approved: MITOXANTRONE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for mitoxantrone hydrochloride from Fresenius Kabi USA, LLC. This approval encompasses the generic p…
-
CLINICAL_TRIALS research · 2011-02-14Clinical Trial Update: Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
An observational registry update documenting treatment patterns in castration-resistant prostate cancer; the study sponsored by Sanofi has b…